Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
TASE:NVLG
Want to see IL:NVLG full AI Analyst Report?
Top Page
Novolog
(TASE:NVLG)
Select Model
Select Model
Rating:44Neutral
Price Target:
81.00
▼(-35.82% Downside)
Action:Reiterated
Date:03/28/26
The score is primarily weighed down by deteriorating financial performance—especially the sharp drop in earnings and the shift to negative operating/free cash flow in 2025. Technicals add further pressure with a strong downtrend and oversold momentum, while valuation is only modestly supported by the ~4% dividend despite a high P/E.
Positive Factors
Manageable leverage
A roughly 0.5x debt-to-equity ratio provides structural balance-sheet resilience, lowering refinancing and covenant risk over the next 2–6 months. That capital structure gives management room to fund operations or strategic moves while earnings recover, supporting durable solvency.
Negative Factors
Sharp 2025 revenue and earnings decline
A sudden, large drop in revenue and net income signals potential structural demand, pricing, or volume challenges. Such a step-change weakens margins and operating flexibility, and if persistent could reduce scale economics, supplier terms, and long-term competitiveness over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable leverage
A roughly 0.5x debt-to-equity ratio provides structural balance-sheet resilience, lowering refinancing and covenant risk over the next 2–6 months. That capital structure gives management room to fund operations or strategic moves while earnings recover, supporting durable solvency.
Read all positive factors
Novolog (NVLG) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪426.58M
Dividend Yield3.05%
Average Volume (3M)641.09K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth-10.70%
EPS Growth-89.53%
CountryIL
Employees936
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)<0.01
Shares Outstanding510,874,760
10 Day Avg. Volume285,794
30 Day Avg. Volume641,093
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Novolog Business Overview & Revenue Model
Company Description
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also p...
Novolog Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
63
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.81B | 2.02B | 1.64B | 1.51B | 1.26B |
| Gross Profit | 124.09M | 180.78M | 173.76M | 176.15M | 148.96M |
| EBITDA | 100.75M | 149.39M | 130.14M | 138.53M | 115.92M |
| Net Income | 4.12M | 39.54M | -42.00M | 47.51M | 42.32M |
Balance Sheet | |||||
| Total Assets | 2.15B | 3.04B | 2.79B | 2.43B | 2.29B |
| Cash, Cash Equivalents and Short-Term Investments | 121.77M | 247.60M | 232.94M | 172.81M | 238.71M |
| Total Debt | 183.20M | 198.47M | 215.18M | 212.77M | 166.81M |
| Total Liabilities | 1.78B | 2.65B | 2.39B | 1.97B | 1.86B |
| Stockholders Equity | 356.85M | 368.38M | 371.08M | 436.00M | 424.37M |
Cash Flow | |||||
| Free Cash Flow | -34.22M | 99.78M | 129.06M | 63.16M | 52.75M |
| Operating Cash Flow | -16.50M | 158.52M | 200.01M | 132.65M | 83.39M |
| Investing Cash Flow | -61.92M | -50.55M | -72.60M | -124.95M | -69.07M |
| Financing Cash Flow | -46.02M | -94.59M | -67.71M | -72.96M | 47.49M |
Novolog Technical Analysis
Negative
126.20
Price Trends
101.84
Negative
112.88
Negative
122.48
Negative
Market Momentum
-5.38
Positive
20.68
Positive
13.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NVLG, the sentiment is Negative. The current price of 126.2 is above the 20-day moving average (MA) of 92.40, above the 50-day MA of 101.84, and above the 200-day MA of 122.48, indicating a bearish trend. The MACD of -5.38 indicates Positive momentum. The RSI at 20.68 is Positive, neither overbought nor oversold. The STOCH value of 13.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NVLG.
Novolog Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₪1.55B | 84.57 | ― | ― | 35.83% | ― | |
77 Outperform | ₪1.76B | 58.47 | 10.95% | ― | 16.36% | 87.37% | |
63 Neutral | ₪2.72B | 16.01 | ― | 2.98% | 4.37% | 396.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | ₪426.58M | -28.50 | ― | 3.05% | -10.70% | -89.53% |
* Healthcare Sector Average
IL:NVLG
Novolog
83.50
-54.54
-39.51%
IL:BWAY
Brainsway
4,404.00
2,489.00
129.97%
IL:ILX
Ilex Medical
4,753.00
-1,173.78
-19.80%
IL:DANE
Danel
46,120.00
9,468.03
25.83%
IL:REKA
Rekah
1,121.00
-258.00
-18.71%
IL:SOFW
Sofwave
4,281.00
2,148.00
100.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.